Phase II, Dose Ranging, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Pilot Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of Aplindore in Patients With Early Stage Parkinson's Disease

Trial Profile

Phase II, Dose Ranging, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Pilot Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of Aplindore in Patients With Early Stage Parkinson's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2011

At a glance

  • Drugs Aplindore (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 10 Aug 2011 Company added as trial sponsor as reported by ClinicalTrials.gov.
    • 07 Jun 2009 Efficacy results presented at the 13th International Congress of Parkinson's Disease and Movement Disorders.
    • 15 Oct 2008 Positive top-line results announced by Neurogen Corporation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top